API5抗体;API5 Antibody—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-4: Hela cells, MCF7 cells, A549 cells, Lovo cells, Primary antibody: P11467(API5 Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

API5 (Apoptosis Inhibitor 5), also known as AAC-11 or FIF, is a nuclear protein initially identified for its role in suppressing apoptosis. It interacts with key apoptotic regulators, such as FGF2 (fibroblast growth factor 2), to inhibit caspase-dependent cell death pathways. API5 is upregulated in various cancers, including breast, lung, and cervical cancers, where its overexpression correlates with tumor progression, metastasis, and resistance to chemotherapy. Studies suggest API5 promotes cell survival by stabilizing anti-apoptotic proteins like Bcl-2 and enhancing AKT phosphorylation, while also modulating transcription factors such as E2F1 to drive cell cycle progression. Additionally, API5 influences immune evasion by suppressing pro-inflammatory cytokine production, making it a potential target for cancer immunotherapy.

The development of API5 antibodies has gained attention for their therapeutic and diagnostic potential. Preclinical studies show that neutralizing API5 antibodies can inhibit tumor growth in mouse models by restoring apoptosis sensitivity and blocking pro-survival signaling. These antibodies may also synergize with conventional therapies to overcome drug resistance. Challenges remain in optimizing specificity and delivery, but API5 remains a promising biomarker and therapeutic candidate in oncology research. Further investigations are needed to clarify its interactions with immune cells and its role in non-cancerous pathologies.